



Charles River Laboratories Continues Commitment to Oncology Drug Discovery

November 13, 2018

Team of oncology experts expand data in Tumor Model Compendium and present strong portfolio at industry conferences

WILMINGTON, Mass.--(BUSINESS WIRE)--Nov. 13, 2018-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced new additions to the [Tumor Model Compendium](#). Charles River's Compendium provides access to a comprehensive collection of well-established tumor models for early-stage oncology research.

The most recent Compendium update adds gastric and liver models, as well as new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer. The newest additions to the Compendium provide oncology researchers access to data that allows them to identify the most appropriate tumor models, leading to a more targeted study design from the start, saving time and money on the path to the clinic.

The Compendium includes tumor models from a wide range of tumor subtypes for both *in vivo* and *in vitro* oncology research, including [patient-derived xenografts](#) (PDXs), cell line-derived xenografts (CDX), and [syngeneic models](#).

Presence at Scientific Conferences

The Compendium is just one example of Charles River's commitment to oncology research. Charles River experts presented four posters at the Society for Immunotherapy's (SITC) 33rd Annual Meeting and will present nine posters at the European Organisation for Research and Treatment of Cancer (EORTC) Conference in Dublin, Ireland.

Noteworthy posters include:

- **Modulation of adenosine levels in the tumor microenvironment following treatment with anti-PD1 antibodies and oxaliplatin: an *in vivo* microdialysis study (Presented at SITC's 33rd Annual Meeting by Arash Rassoulpour)**
Utilizing *in vivo* microdialysis, a technique that has been prominent in neuroscience research for over 50 years, Charles River researchers monitored oncometabolites and immunomodulators directly in the tumor microenvironment.
- **Development of a disseminated AML mouse model to evaluate the therapeutic activity of immune checkpoint inhibitors using bioluminescence imaging (To be presented at EORTC by David Harris)** Charles River researchers developed a disseminated AML disease model to evaluate the therapeutic response to immune checkpoint inhibitors, PD-1, PD-L1 and CTLA-4.

A full schedule of Charles River's activities during [SITC's 33rd Annual Meeting](#) and [EORTC](#) is available online, with poster reprint available after the conferences. Reprints of posters presented at EORTC will also be available in booth A2 during the show.

Approved Quotes

- "The power of our oncology portfolio is stronger than ever. Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need." --Birgit Girshick, Corporate Executive Vice President, Discovery and Safety Assessment, Charles River
- "Since its inception, our Tumor Model Compendium has made finding the best research model for oncology research easier. We are excited about the latest additions and are proud to offer this important resource to oncology researchers." --Julia Schueler, Research Director, Charles River

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20181113005164/en/>

Source: Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc.

Investor Contact:

Todd Spencer, 781-222-6455

Corporate Vice President, Investor Relations

todd.spencer@crl.com

or

Media Contact:

Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
amy.cianciaruso@crl.com